-
July of this year represented the 5-year anniversary of the publication of Gynecologic Oncology Group (GOG) protocol 178, a pivotal trial demonstrating the significant impact of 9 additional months of paclitaxel chemotherapy to women who had achieved a complete clinical response to primary therapy.
-
In the Issue: Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions.
-
Cigarettes and pregnancy are a risky combination, and there is an abundance of data to indicate that perinatal outcome is improved if patients can abstain from smoking.
-
-
Of note, this publication is a review article and not original science. Because of its efficacy and convenience, DMPA has been used by millions of women in the United States and around the world.
-
The lift study (Long-Term Intervention on Fractures with Tibolone) was a randomized, placebo-controlled multicenter trial in 22 countries of tibolone, 1.25 mg, given daily over 3 years.
-
The objective of this study was to examine and compare the clinical behavior and outcome of uterine carcinosarcoma relative to grade 3 endometrioid carcinoma.
-
Fetal fibronectin is now being used in many hospitals to separate out those with preterm contractions (PTCs) who are in true labor from those with contractions who are not (and, therefore, not requiring tocolytics or hospitalization).
-
In this issue: Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
Newcomb and colleagues reported breast cancer mortality in the Collaborative Breast Cancer Study Cohort, a prospective cohort of 12,269 postmenopausal women from Wisconsin, Massachusetts, or New Hampshire.
